After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene Patents
نویسندگان
چکیده
Genetic testing is becoming more common and more powerful by the day. The costs of the underlying DNA sequencing technology are plummeting, making it likely that tests based on it will become even more pervasive. The use of tests to determine DNA sequence to help make clinical decisions is here to stay. DNA sequencing is also finding new uses in forensics, determination of ancestry, understanding the history and genetic lineages of human populations and many other applications.
منابع مشابه
Who owns human genes?: Is DNA patentable?
Angelina Jolie’s recent disclosure that she had undergone a prophylactic double mastectomy following a positive test for a BRCA1 mutation (which increases lifetime breast cancer risk by 60%-87%) prompted a national conversation about genetic testing and preventive surgery.1 Tests for BRCA1 and BRCA2 cost more than $3000, placing them beyond the reach of many women. The high cost is partly a con...
متن کاملTake off your genes and let the doctor have a look: why the Mayo and Myriad decisions have invalidated method claims for genetic diagnostic testing.
Ass'n for Molecular Pathology v. U.S. Patent & Trade Office sent shockwaves through the legal community, when the U.S. District Court for the Southern District of New York rejected a series of patents held by Myriad Genetics, Inc. The court invalidated all of Myriad's compositional patents for human genes and its method patents for diagnosing genetic predispositions to breast cancer. While comm...
متن کاملSupreme Court ruling broadens BRCA testing options.
T he day after Mother's Day, actress Angelina Jolie wrote an op-ed in the New York Times revealing her decision to undergo a double mastectomy after learning that she carries a deleterious mutation in the BRCA1 gene. Jolie and women like her who have certain germ-line BRCA1 or BRCA2 mutations are at higher risk for breast and ovarian cancers. Jolie, whose mother died from ovarian cancer, said s...
متن کاملGene patents at the Supreme Court: Association for Molecular Pathology v. Myriad Genetics
INTRODUCTION In June 2013, the Supreme Court unanimously decided Assn. for Molecular Pathology v. Myriad Genetics Inc., ruling that isolated naturally occurring sequences of genomic DNA (gDNA) cannot be patented. The Court left open the possibility of patenting complementary DNA (cDNA)—synthetic DNA containing the same protein-coding information as a segment of natural DNA but omitting non-codi...
متن کاملSupreme Court Decision on Gene Patents
In a decision having implications for the healthcare, biotechnology, and pharmaceutical industries, on June 13, 2013, the U.S. Supreme Court held that a naturally occurring DNA sequence is not patentable simply because it has been isolated from surrounding genetic material. Assoc. for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. ___ (2013). The Court observed that Myriad’s claims to n...
متن کامل